- Home
- MRSN vs SCLX Comparison
MRSN vs SCLX Comparison
Compare MRSN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- SCLX
- Stock Information
- Founded
- MRSN 2001
- SCLX 2011
- Country
- MRSN United States
- SCLX United States
- Employees
- MRSN N/A
- SCLX N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- SCLX Health Care
- Exchange
- MRSN Nasdaq
- SCLX Nasdaq
- Market Cap
- MRSN 34.0M
- SCLX 35.7M
- IPO Year
- MRSN 2017
- SCLX N/A
- Fundamental
- Price
- MRSN $6.75
- SCLX $12.94
- Analyst Decision
- MRSN Strong Buy
- SCLX Strong Buy
- Analyst Count
- MRSN 5
- SCLX 3
- Target Price
- MRSN $5.75
- SCLX $367.50
- AVG Volume (30 Days)
- MRSN 130.5K
- SCLX 225.6K
- Earning Date
- MRSN 08-12-2025
- SCLX 08-12-2025
- Dividend Yield
- MRSN N/A
- SCLX N/A
- EPS Growth
- MRSN N/A
- SCLX N/A
- EPS
- MRSN N/A
- SCLX N/A
- Revenue
- MRSN $34,006,000.00
- SCLX $50,710,000.00
- Revenue This Year
- MRSN N/A
- SCLX $68.30
- Revenue Next Year
- MRSN $1.03
- SCLX $124.48
- P/E Ratio
- MRSN N/A
- SCLX N/A
- Revenue Growth
- MRSN N/A
- SCLX 7.79
- 52 Week Low
- MRSN $6.47
- SCLX $3.60
- 52 Week High
- MRSN $70.75
- SCLX $57.75
- Technical
- Relative Strength Index (RSI)
- MRSN 38.74
- SCLX 66.20
- Support Level
- MRSN $6.55
- SCLX $10.14
- Resistance Level
- MRSN $10.25
- SCLX $17.76
- Average True Range (ATR)
- MRSN 0.70
- SCLX 1.77
- MACD
- MRSN -0.20
- SCLX 0.68
- Stochastic Oscillator
- MRSN 5.41
- SCLX 58.41
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.